Is Recursion’s new London hub an epicentre of drug discovery?

London, UK

Recursion has announced plans to open a new office in June 2024. The site will provide Recursion and Valence Labs, the company’s artificial intelligence (AI) research engine, with access to European talent and a life science ecosystem from which to work.

Chris Gibson, Co-founder and CEO at Recursion, said: “London stood out as an ideal location given its brilliant and interdisciplinary talent across the fields of technology, biology and chemistry. It’s also the epicentre for the rapidly growing TechBio sector in Europe, where leading technology and life science companies like Google and Merck both sit within walking distance of our new Recursion site. I look forward to expanding our operations in Europe and hiring many new Recursionauts who will help us advance our mission of decoding biology to radically improve lives.”

The company has also announced the addition of Michael Bronstein, DeepMind Professor of Artificial Intelligence at Oxford University, as a Scientific Advisor. Professor Bronstein works in geometric deep learning, graph neural networks, and protein design. Professor Bronstein joins AI Professor Yoshua Bengio in supporting Recursion and Valence Labs in the development of AI models to support the industrialisation of drug discovery.

Megan Thomas, Multimedia Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free